Dr. Sharon Anavi-Goffer
Pharmacology of cannabinoids, Dept. Behavioral Sciences, Ariel University
Dr. Anavi-Goffer is a senior lecturer at Ariel University. Her lab focuses on the psychopharmacology of cannabinoids and translational research aimed at developing small molecules for schizophrenia and Tourette Syndrome. In 2009, Dr. Anavi-Goffer set up the AlphaScreen® Surefire® assay at University of Aberdeen, Scotland. This new platform was awarded the translational biology award from the Scottish Universities Life Sciences Alliance (SULSA). The results were published in the Journal of Biological Chemistry and patented by GW Pharmaceuticals, UK. Dr. Anavi-Goffer also worked for three years as R&D scientist at Pharmos Ltd. Israel, developing selective drugs for CB2 receptors to treat autoimmune diseases.